LIVERPOOL Cryoplateable Hepatocytes

Type:Cell Products
APPLICATION & SPECIALITY USES:ADME-Toxicology Products and Services



LIVERPOOL® cryoplateable human hepatocytes are used for long term studies (>4-6 hours) like induction, toxicity, and transport. More recently, scientists also have been using cryoplateable hepatocytes to study transporter uptake, viral transduction and gene induction.

BioIVT’s LIVERPOOL cryoplateable human hepatocytes have high levels of induction following treatment with known inducers omeprazole (CYP1A2), phenobarbital (CYP2B6), and rifampin (CYP3A4). All plateable lots have greater than 70% viability and greater than 70% confluence on day 5. Cells are also treated with CDFDA fluorescent dye to show bile caniculi formation.

Features and Benefits

  • Purpose-Pooled. A proprietary algorithm, drawing up a cell database of known substrate performances, selects cryoplateable hepatocytes lots from a well-characterized cell bank to achieve targeted enzyme levels.
  • Characterization. All LIVERPOOL products are fully characterized across numerous substrates to ensure consistency and reliability.
  • Format Choice. Available in 5- and 10-donor pool sizes.
  • Savings. In both time and money, LIVERPOOL hepatocytes enable researchers to eliminate pooling procedures, characterization testing and costly multi-donor work.
  • Large Lot Sizes. All contributory hepatocyte lots are sourced from whole, intact, transplant-quality livers, ensuring each donor lot can create large product sizes. This enables researchers to have great consistency across multiple experiments.
  • Quality. All LIVERPOOL lots must meet and exceed stringent quality control specifications prior to release.

The process for producing the LIVERPOOL human hepatocyte products are covered by one or more U.S. or foreign patents and patent applications, including U.S. Patent No. 7,604,929.

Caution: Treat all products containing human materials as potentially infectious, as no known test methods can offer assurance that products derived from human tissues will not transmit infectious agents.

All products are for research use only. Do not use in animals or humans. These products have not been approved for any diagnostic or clinical procedures.

Cryoplateable human hepatocytes are >80% viable and contain a minimum of 5 million cells per vial as determined by Trypan Blue exlcusion.

Cryoplateable human hepatocytes have a :  ≥70% confluent monolayer on day 5

BioIVT provides’ technical support to our customers and this support includes onsite demos or training for handling our hepatocyte, microsome and S9. We have a group of Scientific Advisors that regularly visit customers to discuss their research and ongoing studies. If there are any questions or concerns about the use of our products or a protocol contact our Scientific Advisors for additional help.